| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Acyclovir monophosphate targets viral DNA polymerase after further phosphorylation to acyclovir triphosphate. The monophosphate itself is not the active antiviral agent; it must be further phosphorylated by cellular kinases to the triphosphate form. Acyclovir triphosphate inhibits viral DNA polymerase by competing with dGTP and causing chain termination. The compound is used in research on acyclovir metabolism and antiviral mechanisms.
|
|---|---|
| ln Vitro |
Acyclovir monophosphate is a substrate for cellular kinases that convert it to acyclovir diphosphate and then to acyclovir triphosphate. In vitro, acyclovir monophosphate shows antiviral activity only after conversion to the triphosphate. The compound's activity is typically evaluated in enzyme assays measuring the phosphorylation of acyclovir monophosphate by cellular kinases.
|
| ln Vivo |
Not applicable; Acyclovir monophosphate is an intermediate and is not evaluated for in vivo therapeutic activity as a standalone compound.
|
| Enzyme Assay |
In vitro kinase assays using cellular kinases (e.g., GMP kinase, other nucleoside monophosphate kinases). The enzyme is incubated with acyclovir monophosphate and ATP, and the formation of acyclovir diphosphate or triphosphate is measured by HPLC or mass spectrometry. Kinetic parameters (Km, Vmax) are determined by varying substrate concentrations.
|
| Cell Assay |
In vitro cell-based assays using virus-infected cells. Cells are treated with acyclovir monophosphate at various concentrations (typically 0.1-100 µM) for 3-7 days. Viral replication is assessed by plaque reduction assay or by measuring viral DNA by qPCR. The phosphorylation of acyclovir monophosphate to the triphosphate is assessed by measuring intracellular nucleotide levels by HPLC or mass spectrometry.
|
| Animal Protocol |
Not applicable as this compound is not evaluated in animal models.
|
| References |
| Molecular Formula |
C8H12N5O6
|
|---|---|
| Molecular Weight |
305.1868
|
| Exact Mass |
305.052
|
| CAS # |
66341-16-0
|
| Related CAS # |
Acyclovir alaninate;84499-64-9
|
| PubChem CID |
135422933
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
716.0±70.0 °C at 760 mmHg
|
| Melting Point |
>400ºC
|
| Flash Point |
386.8±35.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.780
|
| LogP |
-2.21
|
| tPSA |
175.39
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
20
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1=NC(=O)C2N=CN(COCCOP(=O)(O)O)C=2N1
|
| InChi Key |
KUOAJOVOKFATQE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H12N5O6P/c9-8-11-6-5(7(14)12-8)10-3-13(6)4-18-1-2-19-20(15,16)17/h3H,1-2,4H2,(H2,15,16,17)(H3,9,11,12,14)
|
| Chemical Name |
2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]ethyl dihydrogen phosphate
|
| Synonyms |
Acyclovir monophosphate Acyclo-GMP.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2766 mL | 16.3832 mL | 32.7665 mL | |
| 5 mM | 0.6553 mL | 3.2766 mL | 6.5533 mL | |
| 10 mM | 0.3277 mL | 1.6383 mL | 3.2766 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.